Internet and Psychiatry
  • Home
    • Editorials
    • Research news
    • Research papers
    • Interviews with eminent psychiatrists
    • Ten years ago
    • Fifteen years ago
  • Topics
    • Alcohol and Drug Abuse
    • Anxiety Disorders
    • Biomedical Science
    • Compulsive gambling
    • Disaster Medicine
    • Education
    • General Medicine
      • Acupuncture
      • Physical medicine and Rehabilitation
    • Human Rights
    • Interviews with eminent psychiatrists
    • Mood Disorders
      • Bipolar Disorder
      • Depression
      • Seasonal Affective Disorder
    • Neurological Disorders
    • Other Psychiatric Disorders
    • Posttraumatic Stress Disorder
    • Sexual Behavior
  • Books
    • Comorbidity of Depression and Alcohol Use Disorders
    • “Immigration and Mental Health” chapter abstracts
    • “Internet and Suicide” chapter abstracts
    • “Neurobiology of PTSD” chapter abstracts
    • “Suicidal Behavior in Alcohol…” chapter abstracts
    • “Suicide in the Military” chapter abstracts
    • “Terror and Suicide” chapter abstracts
    • “War and Suicide” chapter abstracts
  • Editors
    • Leo Sher, M.D.
    • Alexander Vilens, M.S.
  • Guests
    • Distinguished Guests
    • Our Contributors
  • Reflections
    • Poetry
    • Quotes

Ten years ago

Combined dexamethasone suppression-corticotrophin-releasing hormone stimulation test in medication-free individuals with major depression and healthy controls

December 3, 2023

Leo Sher, M.D.

Our research report, “Combined dexamethasone suppression-corticotrophin-releasing hormone stimulation test in medication-free major depression and healthy volunteers” was published 10 years ago in the December 2013 issue of the Journal of Affective Disorders (1).

A combined dexamethasone suppression– corticotrophin-releasing hormone stimulation (DEX–CRH) test has been developed as a potentially sensitive measure of hypothalamic–pituitary–adrenal (HPA) axis dysfunction in mood disorders. In this test, dexamethasone is administered orally at night to suppress cortisol, and then subjects receive an i.v. bolus of CRH in the afternoon of the following day. This approach measures HPA function downstream from CRH, including cortisol feedback or dexamethasone inhibition of adrenocorticotropic hormone (ACTH).

We compared cortisol and ACTH responses in individuals with major depression and healthy volunteers to the DEX–CRH test. Unlike other published studies, the study patients were medication-free, and the healthy volunteers did not have first-degree relatives with a mood or psychotic disorder. This is important because abnormal cortisol reactivity measured using the DEX–CRH test has been reported in adults without psychopathology but having first-degree relatives with mood disorders. Demographics, DSM-IV diagnoses, and other clinical parameters were evaluated in patients with major depressive disorder (MDD) and healthy controls. Participants received an oral dose of 1.5 mg dexamethasone at 11 pm the day before CRH administration. On the following day, at 3 pm, 100 micrograms of ovine CRH were infused. Blood samples for determination of cortisol and ACTH were collected every 15 min from 3 pm to 4:15 pm. Cortisol and ACTH responses were calculated as areas under the curve.

We found no difference between cortisol baseline (i.e., post-dexamethasone) levels in patients and controls with or without controlling for age. We also observed no difference in cortisol responses in patients and controls, with or without controlling for age, and for both age and baseline cortisol levels. Controlling for age, baseline (i.e., post-dexamethasone) ACTH levels were higher in depressed patients compared to controls (p=0.01). There was a trend for higher ACTH responses in depressed patients compared to the control group (p=0.08). In depressed patients, cortisol and ACTH responses correlated positively with age, duration of illness and number of hospitalizations.

This study showed a dissociation of plasma ACTH and plasma cortisol in the DEX–CRH test in patients with MDD as compared to healthy controls. Our results suggest that the feedback inhibition of ACTH secretion by cortisol is compromised in MDD.

This study was supported by the American Foundation for Suicide Prevention grant to Dr. Leo Sher.

Reference

1. Sher L, Oquendo MA, Burke AK, Cooper TB, Mann JJ. Combined dexamethasone suppression-corticotrophin-releasing hormone stimulation test in medication-free major depression and healthy volunteers. J Affect Disord. 2013 Dec;151(3):1108-12. doi: 10.1016/j.jad.2013.06.049. Epub 2013 Jul 15.

Related Posts

Ten years ago /

Suicide malpractice

Ten years ago /

Testosterone levels and future suicide attempts in women with bipolar disorder

Ten years ago /

Bipolar disorder, testosterone administration, and homicide

‹ Regular sleep patterns are more important to health and longevity than spending eight hours in bed › Suicide in individuals with no psychiatric disorders

Editorials

  • The role of the h-index in academic medicine
  • A timeless commitment: Reflections on the Hippocratic Oath
  • Abraham Flexner history: Celebrated medical educator – improved physician training, yet also left a not well-known legacy  
  • Suicide medical malpractice: A conceptual perspective

Research Papers

  • COVID-19 mortality in Europe and the ’Iron Curtain’ between East and West
  • Examination of depressive signs and symptoms among 803 University students in seven Universities and Colleges. Hungary, Romania, Serbia.
  • Examination of spirituality and the dimensions of spirituality among 803 students in seven different Universities. Hungary, Romania and Serbia.
  • Examination of depressive signs and symptoms among 932 students in eight different secondary schools in Hungary

Research News

  • Blood alcohol concentration and suicide mortality in Finland
  • Suicide risk in older adults: clinical responsibilities and medico-legal considerations
  • Conceptualizing a combat veteran’s suicide death through the stress-diathesis model
  • No evidence of a causal link between glucagon-like peptide-1 receptor agonists and suicidal behavior

Latest News

  • FDA launches real-time clinical trial initiative
  • The 2025 ScholarGPS rankings of leading scholars in suicidology
  • Mental health support for healthcare professionals
  • The 2024 ScholarGPS ranking of scholars in the field of suicidology

Interviews with eminent psychiatrists

  • 2026 Interview with Professor Zoltan Rihmer
  • 2026 Interview with Doctor María Dolores Braquehais Conesa
  • 2026 Interview with Professor Shih-Ku Lin
  • Interview with Professor Jess G. Fiedorowicz

Ten Years Ago

  • Suicide malpractice
  • Testosterone levels and future suicide attempts in women with bipolar disorder
  • Bipolar disorder, testosterone administration, and homicide
  • The cosyntropin stimulation test in military veterans with or without posttraumatic stress disorder

Back to Top

  • About
  • Contact
  • Privacy Policy
  • Terms and Conditions
Copyright © 2025 AVCalc LLC. All rights reserved worldwide.